Literature DB >> 9218525

Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

L W Castellani1, M Navab, B J Van Lenten, C C Hedrick, S Y Hama, A M Goto, A M Fogelman, A J Lusis.   

Abstract

Previous studies showed that transgenic mice overexpressing either apolipoprotein AI (apoAI) or apolipoprotein AII (apoAII), the major proteins of HDL, exhibited elevated levels of HDL cholesterol, but, whereas the apoAI-transgenic mice were protected against atherosclerosis, the apoAII-transgenic mice had increased lesion development. We now examine the basis for this striking functional heterogeneity. HDL from apoAI transgenics exhibited an enhanced ability to promote cholesterol efflux from macrophages, but HDL from apoAII transgenics and nontransgenics were not discernibly different in efflux studies. In contrast with HDL from nontransgenics and apoAI transgenics, HDL from the apoAII transgenics were unable to protect against LDL oxidation in a coculture model of the artery wall. Furthermore, HDL taken from apoAII-transgenic mice, but not HDL taken from either the apoAI transgenics or nontransgenic littermate controls, by itself stimulated lipid hydroperoxide formation in artery wall cells and induced monocyte transmigration, indicating that the apoAII-transgenic HDL were in fact proinflammatory. This loss in the ability of the apoAII-transgenic HDL to function as an antioxidant/antiinflammatory agent was associated with a decreased content of paraoxonase, an enzyme that protects against LDL oxidation. Reconstitution of the apoAII transgenic HDL with purified paraoxonase restored both paraoxonase activity and the ability to protect against LDL oxidation. We conclude that overexpression of apoAII converts HDL from an anti- to a proinflammatory particle and that paraoxonase plays a role in this transformation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218525      PMCID: PMC508211          DOI: 10.1172/JCI119554

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Influence of high density lipoprotein on esterified cholesterol stores in macrophages and hepatoma cells.

Authors:  D W Bernard; A Rodriguez; G H Rothblat; J M Glick
Journal:  Arteriosclerosis       Date:  1990 Jan-Feb

2.  Modification of the Recalde method for the isolation of human monocytes.

Authors:  A M Fogelman; F Elahi; K Sykes; B J Van Lenten; M C Territo; J A Berliner
Journal:  J Lipid Res       Date:  1988-09       Impact factor: 5.922

3.  Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells.

Authors:  M Navab; G P Hough; L W Stevenson; D C Drinkwater; H Laks; A M Fogelman
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid.

Authors:  M Kawano; T Miida; C J Fielding; P E Fielding
Journal:  Biochemistry       Date:  1993-05-18       Impact factor: 3.162

5.  Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles.

Authors:  R Barbaras; P Puchois; J C Fruchart; G Ailhaud
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

6.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction.

Authors:  J McElveen; M I Mackness; C M Colley; T Peard; S Warner; C H Walker
Journal:  Clin Chem       Date:  1986-04       Impact factor: 8.327

7.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.

Authors:  C H Warden; C C Hedrick; J H Qiao; L W Castellani; A J Lusis
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

8.  Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders.

Authors:  E Pavković; V Simeon; E Reiner; M Sućić; V Lipovac
Journal:  Chem Biol Interact       Date:  1993-06       Impact factor: 5.192

9.  Cholesterol esters selectively delivered in vivo by high-density-lipoprotein subclass LpA-I to rat liver are processed faster into bile acids than are LpA-I/A-II-derived cholesterol esters.

Authors:  M N Pieters; G R Castro; D Schouten; P Duchateau; J C Fruchart; T J Van Berkel
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

10.  High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3.

Authors:  A Walsh; Y Ito; J L Breslow
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

View more
  30 in total

1.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

2.  High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; H A Neil; P C Adams
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

3.  ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis.

Authors:  Yaoyong Wang; Jinko Sawashita; Jinze Qian; Beiru Zhang; Xiaoying Fu; Geng Tian; Lei Chen; Masayuki Mori; Keiichi Higuchi
Journal:  J Lipid Res       Date:  2011-05-26       Impact factor: 5.922

4.  Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis.

Authors:  Diana M Shih; Zeneng Wang; Richard Lee; Yonghong Meng; Nam Che; Sarada Charugundla; Hannah Qi; Judy Wu; Calvin Pan; J Mark Brown; Thomas Vallim; Brian J Bennett; Mark Graham; Stanley L Hazen; Aldons J Lusis
Journal:  J Lipid Res       Date:  2014-11-06       Impact factor: 5.922

5.  High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli.

Authors:  Loren E Smith; Jun Yang; Leah Goodman; Xinqi Huang; Rong Huang; James Dressman; Jamie Morris; R A Gangani D Silva; W Sean Davidson; Giorgio Cavigiolio
Journal:  J Lipid Res       Date:  2012-05-25       Impact factor: 5.922

6.  Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.

Authors:  Yao Wang; Manabu Niimi; Kazutoshi Nishijima; Ahmed Bilal Waqar; Ying Yu; Tomonari Koike; Shuji Kitajima; Enqi Liu; Tomohiro Inoue; Masayuki Kohashi; Yuka Keyamura; Tomohiro Yoshikawa; Jifeng Zhang; Loretta Ma; Xiaohui Zha; Teruo Watanabe; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-12-13       Impact factor: 8.311

7.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

8.  Is elevated high-density lipoprotein cholesterol always good for coronary heart disease?

Authors:  Yuhua Sun; Yuejin Yang; Weidong Pei; Yongjian Wu; Jinglin Zhao
Journal:  Clin Cardiol       Date:  2007-11       Impact factor: 2.882

9.  Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties.

Authors:  Lourdes Rodrigo; Fernando Gil; Antonio F Hernandez; Olga Lopez; Antonio Pla
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

10.  Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein.

Authors:  Patricia A Thompson; Jimmy F P Berbée; Patrick C N Rensen; Richard L Kitchens
Journal:  Innate Immun       Date:  2008-12       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.